Moderna has unveiled plans for new funding commitments to increase supply at its owned and partnered manufacturing facilities, which it expects will increase global 2022 capacity to up to 3 billion doses of its COVID-19 vaccine, depending upon the mix between the authorized Moderna COVID-19 Vaccine at the 100 μg dose level and potentially lower doses of the company’s variant booster candidates and pediatric vaccines, if authorized.   These investments allow for a doubling of drug substance manuf...